Bernd Seizinger, CEO of GPC Biotech, said: “We are disappointed, but we understand Celgene’s decision given their recent withdrawal of the marketing authorization application for satraplatin in Europe.
“We plan to decide in the near future the next steps regarding the development of satraplatin, and we will continue to focus our other efforts on advancing our RGB-286638 kinase inhibitor into the clinic and exploring various merger and acquisition opportunities.”